Drugs & Aging

, Volume 22, Issue 3, pp 185–200 | Cite as

Cyclo-Oxygenase-2 Inhibitors

When Should They Be Used in the Elderly?
Current Opinion

Abstract

Chronic pain in the elderly is frequently a result of arthritic disorders, particularly osteoarthritis. The cyclo-oxygenase (COX)-2 inhibitors are as effective as standard NSAIDs for the relief of pain and for improving function in elderly patients with osteoarthritis and rheumatoid arthritis. COX-2 inhibitors increase the risk of serious gastroduodenal adverse reactions but there is evidence that they carry a lower risk for these adverse effects than standard NSAIDs, except when there is concurrent aspirin use. Since gastroduodenal disorders are the most frequently reported serious adverse effects of NSAIDs and these disorders occur more frequently in the elderly, COX-2 inhibitors offer an alternative to standard NSAIDs in this age group. However, they are not appropriate for many patients with cardiovascular and renal disease.

The adverse reaction profile of the COX-2 inhibitors has confirmed the role of the COX-2 enzyme in renal function, salt and water homeostasis and the vascular endothelium. Thus, like standard NSAIDs, COX-2 inhibitors can cause renal failure, hypertension and exacerbation of cardiac failure. Of note is that these disorders are dose related. Thus, there are good reasons to avoid high doses of COX-2 inhibitors in the elderly. Clinical trials indicate that daily doses of rofecoxib 12.5mg, celecoxib 100–200mg, valdecoxib 10mg and etoricoxib 60mg are the minimum effective doses of these agents. Data from the New Zealand Intensive Medicines Monitoring Programme indicate that celecoxib 200 mg/day and rofecoxib 25 mg/day are/were the most commonly prescribed doses and that 6% of patients had taken rofecoxib 50 mg/day for longer than recommended. Recent research indicates that COX-2 inhibitors have a thrombotic potential, especially in high doses and when use is prolonged, and this further limits the extent to which they can be used in the elderly.

Important interactions with COX-2 inhibitors in the elderly include those with warfarin, which can result in loss of control of anticoagulation, and those with ACE inhibitors, angiotensin II type 1 receptor antagonists and diuretics, which can result in loss of control of blood pressure and cardiac failure and, in hypovolaemic conditions, renal failure. The clinical significance of an interaction between celecoxib and aspirin to reduce the antiplatelet effect of the latter drug is unknown.

Preliminary information from spontaneous reporting systems indicates that there may be differences in the risk of cardiac failure and hypertension between standard NSAIDs and COX-2 inhibitors and between rofecoxib and celecoxib. More formal studies using equivalent doses are needed to test this observation.

Use of COX-2 inhibitors may be considered in the elderly to reduce the risk of gastroduodenal complications associated with standard NSAIDs but only when consideration has first been given to use of less toxic medicines as alternatives or supplements, the appropriate dose of the COX-2 inhibitor or standard NSAID, the presence and possible impact of co-morbidities, and the implications of taking COX-2 inhibitors with any concomitant medications. Equally important is regular monitoring of the patient taking a COX-2 inhibitor for efficacy and adverse effects, and ensuring that the patient has a continuing need to keep taking the drug. Close attention also needs to be paid to intercurrent illnesses and new prescriptions that may reduce the safety of the COX-2 inhibitor.

A standard NSAID plus a proton pump inhibitor may be equally effective as a COX-2 inhibitor in reducing the risk of gastroduodenal toxicity and if used the same prescribing advice applies. Current knowledge concerning the thrombotic potential of COX-2 inhibitors suggests that this combination, if tolerated, may be preferable to a COX-2 inhibitor, particularly where prolonged use is required. This knowledge also indicates that for patients with or at high risk of ischaemic heart disease or stroke, COX-2 inhibitors are contraindicated.

Notes

Acknowledgements

The author acknowledges the assistance of Mrs Janelle Ashton of the New Zealand Pharmacovigilance Centre in collecting and collating references. The New Zealand Pharmacovigilance Centre operates through a grant from Medsafe a unit of the New Zealand Ministry of Health. The opinions expressed in this article are the personal opinions of the author.

The author has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002; 14(5): 573–7PubMedCrossRefGoogle Scholar
  2. 2.
    Rang HP, Dale MM, Ritter JM. Anti-inflammatory and immunosuppressive drugs. In: Rang HP, Dale MM, Ritter JM, editors. Pharmacology. 4th ed. Sydney: Churchill Livingstone, 1999: 229–34Google Scholar
  3. 3.
    Langman MJS. Ulcer complications associated with anti-inflammatory drug use: what is the extent of the disease burden? Pharmacoepidemiol Drug Saf 2001; 10: 13–9PubMedCrossRefGoogle Scholar
  4. 4.
    Page J, Henry D. Consumption of NSAIDs and the development of heart failure in elderly patients: an underrecognised public health problem. Arch Intern Med 2002; 160(6): 777–84CrossRefGoogle Scholar
  5. 5.
    Savage RL, Moller PW, Ballantyne CL, et al. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum 1993; 36(1): 84–90PubMedCrossRefGoogle Scholar
  6. 6.
    Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 2003; 20(9): 701–10PubMedCrossRefGoogle Scholar
  7. 7.
    Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325(7365): 624PubMedCrossRefGoogle Scholar
  8. 8.
    National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology No. 27. London: Government Publication, 2001Google Scholar
  9. 9.
    Felson DT. The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments. Arthritis Rheum 2001; 44(7): 1477–80PubMedCrossRefGoogle Scholar
  10. 10.
    Pincus T, Koch GG, Sokka T, et al. A randomized, doubleblind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44(7): 1587–98PubMedCrossRefGoogle Scholar
  11. 11.
    Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial [published erratum appears in JAMA 2002 Feb 27; 287 (8): 989]. JAMA 2002; 287(1): 64–71PubMedCrossRefGoogle Scholar
  12. 12.
    American College of Rheumatology Osteoarthritis Guidelines Subcommittee. Recommendation for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000; 43(9): 1905–15CrossRefGoogle Scholar
  13. 13.
    Harrison A. Disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis: benefits and risks. Prescriber Update 1999; 18: 4–12Google Scholar
  14. 14.
    Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59(4): 957–80PubMedCrossRefGoogle Scholar
  15. 15.
    Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354(9196): 2106–11PubMedCrossRefGoogle Scholar
  16. 16.
    Scott LJ, Lamb HM. Rofecoxib. Drugs 1999; 58(3): 499–505PubMedCrossRefGoogle Scholar
  17. 17.
    Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336–47PubMedCrossRefGoogle Scholar
  18. 18.
    Bextra©. New Zealand data sheet: Pharmacia. 7th February 2003 [online]. Available from URL: http://www.med-safe.govt.nz [Accessed 2005 Feb 15]
  19. 19.
    Arcoxia©. New Zealand data sheet: Merck, Sharp & Dohme (NZ) Ltd. November 2004 [online]. Available from URL: http://www.medsafe.gov.nz [Accessed 2005 Feb 15]
  20. 20.
    Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21: 1–15PubMedCrossRefGoogle Scholar
  21. 21.
    Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102(8): 840–5PubMedCrossRefGoogle Scholar
  22. 22.
    Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345(6): 433–42PubMedCrossRefGoogle Scholar
  23. 23.
    Clark DWJ, Layton D, Shakir SAW. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Drug Saf 2004; 27(7): 427–56PubMedCrossRefGoogle Scholar
  24. 24.
    Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40(10): 1109–20PubMedGoogle Scholar
  25. 25.
    McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96(1): 272–7PubMedCrossRefGoogle Scholar
  26. 26.
    Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558–68PubMedGoogle Scholar
  27. 27.
    Celebrex© New Zealand data sheet. Pfizer New Zealand Ltd [online]. Available from URL: http://www.medsafe.govt.nz [Accessed 2004 Apr 29]
  28. 28.
    Committee on Safety of Medicines: CSM update. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-2. BMJ (Clin Res Ed) 1986; 292: 1190–1CrossRefGoogle Scholar
  29. 29.
    Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282(20): 1929–33PubMedCrossRefGoogle Scholar
  30. 30.
    Bombardier C, Laine L, Reicin A, et al., on behalf of VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343(21): 1520–30PubMedCrossRefGoogle Scholar
  31. 31.
    Silverstein FE, Faich G, Goldstein JL, et al., on behalf of The Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284(10): 1247–55PubMedCrossRefGoogle Scholar
  32. 32.
    FDA Advisory Committee 2000. Celecoxib Medical Officer review (CLASS Study) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf [Accessed 2005 Feb 13]
  33. 33.
    Schnitzer TJ, Burmester GR Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21; 364: 665–74PubMedCrossRefGoogle Scholar
  34. 34.
    Laporte J-R, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs. Drug Saf 2003; 27(6): 411–20CrossRefGoogle Scholar
  35. 35.
    Savage RL. Can patients stomach COX-2 inhibitors? Prescriber Update 2002; 23(2): 26–7Google Scholar
  36. 36.
    Adverse Drug Reactions Advisory Committee (ADRAC). Serious gastrointestinal effects with celecoxib and rofecoxib. Aust Adv Drug Reactions Bull 2003; 22(3): 15Google Scholar
  37. 37.
    Weaver J, Bonnel RA, Karwoski CB, et al. GI events leading to death in association with celecoxib and rofecoxib. Am J Gastroenterol 2001; 96(12): 3449–50PubMedGoogle Scholar
  38. 38.
    Chan FKL, Hung LCT, Sven BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347(26): 2104–10PubMedCrossRefGoogle Scholar
  39. 39.
    Lewis SC, Langman MJS, Laporte J-R, et al. Dose response relationships between individual nonaspirin nonsteroidal antiinflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54(3): 320–6PubMedCrossRefGoogle Scholar
  40. 40.
    Savage RL. NSAIAs can cause lower GIT damage. Prescriber Update 2001; 21: 25–7Google Scholar
  41. 41.
    Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol 2001; 96(4): 1306–8PubMedCrossRefGoogle Scholar
  42. 42.
    Eid RY, Quirk DM. Diaphragm-like strictures of the colon induced by the selective COX-2 inhibitor celecoxib: a case report and review of the literature. Am J Gastroenterol 2001; 96 Suppl.: S194.CrossRefGoogle Scholar
  43. 43.
    Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25(7): 537–44PubMedCrossRefGoogle Scholar
  44. 44.
    Henao J, Hisamuddin I, Nzerue CM, et al. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 2002; 39(6): 1313–7PubMedCrossRefGoogle Scholar
  45. 45.
    Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001; 357: 1946–7PubMedCrossRefGoogle Scholar
  46. 46.
    Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal related-adverse drug reactions between rofecoxib and celecoxib based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23(9): 1478–91PubMedCrossRefGoogle Scholar
  47. 47.
    Bate A, Lindquist M, Edwards IR, et al. Data derived from WHO International Drug Monitoring Database: a data mining approach for signal detection and analysis. Drug Saf 2002; 25(6): 393–7PubMedCrossRefGoogle Scholar
  48. 48.
    Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002; 72(1): 50–61PubMedCrossRefGoogle Scholar
  49. 49.
    Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160(10): 1465–70PubMedCrossRefGoogle Scholar
  50. 50.
    Feenstra J, Heerdink ER, Diederick E, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Intern Med 2002; 162: 265–70PubMedCrossRefGoogle Scholar
  51. 51.
    The WHO International Drug Monitoring Program. Data derived from the WHO International Drug Monitoring Database. In: Aronson JK, editor. Side effects of drugs, annual 26. Amsterdam: Elsevier Science, 2003: 548–57Google Scholar
  52. 52.
    Mamdani M, Juurlink D, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004 May 29; 363: 1751–6PubMedCrossRefGoogle Scholar
  53. 53.
    Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90(9): 959–63PubMedCrossRefGoogle Scholar
  54. 54.
    Weaver A, Alderman M, Sperling R. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. Am J Cardiol 2003; 91(10): 1291–2PubMedCrossRefGoogle Scholar
  55. 55.
    FDA Advisory Committee (2000). Rofecoxib statistical review (VIGOR study) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_04_stats.pdf [Accessed 2005 Feb 13]
  56. 56.
    Brinker A, Goldkind L, Bonnel R, et al. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 2004; 21(7): 479–84PubMedCrossRefGoogle Scholar
  57. 57.
    Farkouh M, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug 21; 364: 675–84PubMedCrossRefGoogle Scholar
  58. 58.
    Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–3PubMedCrossRefGoogle Scholar
  59. 59.
    Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Feb 15 [online]. Available from URL: http://www.nejm.org [Accessed 2005 Feb 15]Google Scholar
  60. 60.
    Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 Feb 5; 365(9458): 475–81PubMedGoogle Scholar
  61. 61.
    Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163: 481–6PubMedCrossRefGoogle Scholar
  62. 62.
    Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068–73PubMedCrossRefGoogle Scholar
  63. 63.
    Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Feb 15 [online]. Available from URL: http://content.nejm.org/cgi/content/abstract/NEJMoa050405v1 [Accessed 2005 Feb 15]
  64. 64.
    Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005; 111(3): 249PubMedCrossRefGoogle Scholar
  65. 65.
    Clark DWJ, Ghose K. Neuropsychiatric reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). Drug Saf 1992; 7(6): 460–8PubMedCrossRefGoogle Scholar
  66. 66.
    Jiang H-K, Chang D-M. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 1999; 18: 339–45PubMedCrossRefGoogle Scholar
  67. 67.
    Coulter DM. Acute psychiatric reactions with COX-2 inhibitors. Prescriber Update 2002; 23(2): 21Google Scholar
  68. 68.
    Coulter DM, Clark DWJ, Savage RL. Celecoxib, rofecoxib and acute temporary visual impairment. BMJ 2003; 327: 1214–5PubMedCrossRefGoogle Scholar
  69. 69.
    Garnett WR. Clinical Implications of drug interactions with the coxibs. Pharmacotherapy 2001; 21(10): 1223–32PubMedCrossRefGoogle Scholar
  70. 70.
    Thomas M, on behalf of ADRAC. Diuretics, ACE inhibitors and NSAIDs: the triple whammy. Med J Aust 2000; 172: 184–5PubMedGoogle Scholar
  71. 71.
    Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited [published erratum appears in Med J Aust 2000; 173: 504]. Med J Aust 2000; 173: 274PubMedGoogle Scholar
  72. 72.
    Savage RL. A dangerous trio. Prescriber Update 2002; 23(2): 20Google Scholar
  73. 73.
    Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenaase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A 2001; 98(25): 14583–5PubMedCrossRefGoogle Scholar
  74. 74.
    Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17PubMedCrossRefGoogle Scholar
  75. 75.
    Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108(10): 1191–5PubMedCrossRefGoogle Scholar
  76. 76.
    Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen and mortality after myocardial infarction: retrospective cohort study. BMJ 2003; 327(7427): 1322–3PubMedCrossRefGoogle Scholar
  77. 77.
    Adverse Drug Reactions Advisory Committee (ADRAC). Interaction of celecoxib and warfarin. Adv Drug React Bull 2001; 20(1): 2Google Scholar
  78. 78.
    Medsafe Editorial Team. Interaction between COX-2 inhibitors and warfarin. Prescriber Update 2001; 22: 16–8Google Scholar
  79. 79.
    Adverse Drug Reactions Advisory Committee (ADRAC). Interaction of rofecoxib and warfarin. Adv Drug React Bull 2002; 21(1): 3Google Scholar
  80. 80.
    Slørdal L, Samstad S, Bathen J, et al. A life-threatening interaction between lithium and celecoxib. Br J Clin Pharmacol 2003 Apr; 55: 413–4PubMedCrossRefGoogle Scholar
  81. 81.
    Collantes-Estevez E, Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PA-VIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 2003; 19(5): 402–10PubMedCrossRefGoogle Scholar
  82. 82.
    Coulter DM. COX-2 inhibitor use in New Zealand: a problem of age and death. In: Davis EA, Sobey CG, editors. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists; 2003 Nov 30–Dec 3; Sydney. Melbourne (VIC): ASCEPT, 2003: 10, 110Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.New Zealand Pharmacovigilence Centre, Department of Preventive and Social MedicineUniversity of OtagoDunedinNew Zealand

Personalised recommendations